Business Context and Reporting Period
Company: Quantum-Si Inc (QSI)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three months ended March 31, 2026
Business Overview: Quantum-Si is a life sciences company focused on proteomics research, developing next-generation protein sequencing (NGPS) platforms. The company currently commercializes the Platinum line of instruments and consumables while developing the next-generation "Proteus" platform, anticipated for launch by the end of 2026.
Key Financial Metrics
| Metric (in thousands) | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenue | $258 | $842 |
| Gross Profit | $74 | $486 |
| Gross Margin | 28.7% | 57.7% |
| Net Loss | $(21,671) | $(19,189) |
| Loss Per Share (Basic & Diluted) | $(0.10) | $(0.11) |
| Operating Cash Flow | $(25,638) | $(26,154) |
| Cash & Marketable Securities | $190,338 | $240,512 |
| Total Liabilities | $12,604 | $25,381 |
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 69.4% to $0.3 million, driven by a 73.3% drop in product revenue. Management attributes this to customers deferring purchases in anticipation of the upcoming Proteus platform launch.
- Margin Compression: Gross margin fell from 57.7% to 28.7% due to a shift in product mix sold during the period.
- Expense Management: Selling, general, and administrative (SG&A) expenses decreased 18.9% to $9.6 million, primarily due to a $1.4 million reduction in legal fees following the resolution of prior litigation. Research and development (R&D) expenses increased 5.6% to $14.5 million to support Proteus development.
- Legal Settlement Resolution: The company settled the Delaware Stockholder Litigation in Q1 2026. The $8.0 million liability recorded in the prior year was fully resolved, with $3.0 million paid in cash and $4.6 million covered by insurance proceeds.
- Investment Activity: Net cash provided by investing activities turned positive ($40.3 million) due to significant sales and maturities of marketable securities ($104.7 million) exceeding purchases ($64.2 million).
Outlook, Risks, and Management Commentary
- Proteus Launch: The Proteus platform is expected to launch by the end of 2026. Management anticipates continued revenue headwinds in 2026 as customers delay purchases of current Platinum instruments pending the new platform's availability.
- Liquidity: As of March 31, 2026, the company held $190.4 million in cash, cash equivalents, and marketable securities. Management believes this is sufficient to fund operations for at least the next 12 months.
- Capital Requirements: The company expects to continue incurring negative operating cash flows until revenue scales. Future funding may require additional equity or debt offerings.
- Risks: Key risks include the timing and success of the Proteus launch, the ability to raise future financing, and potential impacts from global economic conditions, inflation, and supply chain disruptions.
Investor Verification Checklist
- Proteus Timeline: Verify the projected end-of-2026 launch date for the Proteus platform and the specific technical milestones required.
- Revenue Recovery: Assess the magnitude of deferred demand and the expected ramp-up of revenue post-Proteus launch.
- Cash Burn Rate: Monitor the quarterly cash burn rate against the $190.4 million liquidity position to determine the runway for operations.
- Warrant Liability: Review the fair value of outstanding warrant liabilities ($0.4 million) and their potential impact on future earnings volatility.
- Capital Raising: Evaluate the status of the "at-the-market" (ATM) offering program and any plans for future equity dilution.